Boardroom Alpha
Boardroom Alpha
CTEV · Current Report (Form 8-K) · Filed November 14, 2025

Claritev Corp — Current Report (Form 8-K)

Form
8-K
Filed
November 14, 2025
Period
Nov 12, 2025
Ticker
CTEV
Accession
0001104659-25-112555
Boardroom Alpha · Filing insights

Secondary offering by Hellman & Friedman affiliates closed; 1.5 million Class A shares sold at $51.50; company received no proceeds.

About Claritev Corp
Market cap
$483M
1Y TSR
−39.6%
3Y TSR
−31.3%
Board grade
C-
Sector
Healthcare
CEO
Travis Dalton
Last annual meeting: Apr 29, 2026 · View full Claritev Corp profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

November 12, 2025

 

Claritev Corporation

(Exact name of registrant as specified in its charter)

 

Delaware   001-39228   84-3536151

(State or other jurisdiction of incorporation)

  (Commission File Number)   (IRS Employer Identification No.)

 

7900 Tysons One Place, Suite 400

McLean, Virginia 22102

(212780-2000

(Address, including zip code, and telephone number,

including area code, of registrant’s principal executive offices)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange on which registered
Shares of Class A Common Stock, $0.0001 par value per share   CTEV   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01 Other Events

 

On November 12, 2025, Claritev Corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with certain affiliates of Hellman & Friedman (collectively, the “Selling Stockholders”) and Barclays Capital Inc., Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named in Schedule I thereto (collectively, the “Underwriters”), relating to the offer and sale by the Selling Stockholders of 1,500,000 shares of Class A common stock, par value $0.0001 per share, of the Company (the “Class A Common Stock”), at a price to the public of $51.50 per share (the “Offering”). In addition, the Selling Stockholders granted the Underwriters a 30-day option to purchase up to an additional 225,000 shares of Class A Common Stock. The Company did not sell any shares of Class A Common Stock in the Offering and did not receive any proceeds from the sale of the Class A Common Stock by the Selling Stockholders. The Offering closed on November 14, 2025.

 

The Underwriting Agreement contains customary representations and warranties, agreements and obligations, closing conditions and termination provisions. The Company and the Selling Stockholders have agreed to indemnify the Underwriters against certain liabilities and to contribute to payments the Underwriters may be required to make in the event of any such liabilities.

 

The foregoing description of the Underwriting Agreement does not purport to be complete and is subject to and is qualified in its entirety by reference to the Underwriting Agreement, a copy of which is attached hereto as Exhibit 1.1 and the terms of which are incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No. Description
1.1 Underwriting Agreement, dated as of November 12, 2025, among Claritev Corporation, the Selling Stockholders and Barclays Capital Inc., Guggenheim Securities, LLC and Wells Fargo Securities, LLC.
104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 14, 2025

 

Claritev Corporation  
     
By: /s/ Douglas M. Garis  
Name: Douglas M. Garis  
Title: Executive Vice President and Chief Financial Officer  

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Claritev Corp (CTEV)

Reference

Frequently asked questions

When did Claritev Corp file this 8-K?
Claritev Corp (CTEV) filed this Current Report (Form 8-K) with the SEC on November 14, 2025. The accession number assigned by EDGAR is 0001104659-25-112555.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Secondary offering by Hellman & Friedman affiliates closed; 1.5 million Class A shares sold at $51.50; company received no proceeds. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Claritev Corp's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Claritev Corp has filed under CIK 1793229, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer